Amicus Therapeutics (NASDAQ: FOLD) reported Q4 EPS of $0.01, $0.07 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $115.08 million versus the consensus estimate of $114.35 million.

2024 Financial Guidance:

For the full-year 2024, the Company anticipates total Galafold revenue growth between 11% and 16% at CER1 driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Non-GAAP operating expense guidance for the full-year 2024 is $345 million to $365 million, driven by disciplined expense management offset by continued investment in Galafold, Pombiliti + Opfolda clinical studies, as well as global launch activities4.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.